Dimension Therapeutics (DMTX) Rating Reiterated by Chardan Capital
Dimension Therapeutics (NASDAQ:DMTX)‘s stock had its “buy” rating reiterated by equities research analysts at Chardan Capital in a research report issued to clients and investors on Friday.
The analysts wrote, “We believe 2017 has been an even better year fundamentally, on the expansion of breakthrough results, the first 3 GT approvals in the US, sector late-stage momentum, sound safety, and other considerations below. We now make uniQure (Buy) a Chardan Top Pick for 2018 and a Chardan Top Pick in Gene Therapy for 2018.””
Several other brokerages have also commented on DMTX. ValuEngine raised Dimension Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, September 30th. Wells Fargo & Co lowered Dimension Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $9.00 to $6.00 in a research report on Tuesday, October 3rd. Citigroup raised Dimension Therapeutics from a “sell” rating to a “neutral” rating and raised their price objective for the company from $5.50 to $6.00 in a research report on Tuesday, October 3rd. Finally, Canaccord Genuity lowered Dimension Therapeutics from a “buy” rating to a “hold” rating and lowered their price objective for the company from $12.00 to $3.41 in a research report on Wednesday, August 30th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $5.08.
Dimension Therapeutics (NASDAQ:DMTX) last announced its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.20). The firm had revenue of $4.48 million for the quarter. Dimension Therapeutics had a negative net margin of 378.28% and a negative return on equity of 240.95%. equities analysts expect that Dimension Therapeutics will post -1.99 EPS for the current year.
Institutional investors and hedge funds have recently bought and sold shares of the company. Goldman Sachs Group Inc. raised its position in shares of Dimension Therapeutics by 206.7% in the 2nd quarter. Goldman Sachs Group Inc. now owns 80,471 shares of the biotechnology company’s stock worth $117,000 after purchasing an additional 54,231 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new position in shares of Dimension Therapeutics in the 3rd quarter worth about $600,000. Kassirer Asset Management Corp purchased a new position in shares of Dimension Therapeutics in the 3rd quarter worth about $952,000. Finally, K2 Principal Fund L.P. purchased a new position in shares of Dimension Therapeutics in the 3rd quarter worth about $960,000. 70.33% of the stock is owned by hedge funds and other institutional investors.
Dimension Therapeutics Company Profile
Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).
Receive News & Ratings for Dimension Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.